Skip to main content
. 2012 Sep 26;12:431. doi: 10.1186/1471-2407-12-431

Table 2.

Characteristics of samples used in this study grouped by responses of cells to Tipifarnib and GO: CD34+CD38-cells

AML# %CD34+CD38- CD123 MFI CD33 MFI Tip% cell loss1 GO%cell loss1 Tip/GO%cell loss1 Δtox2
#13
 3
 92
 —
 88
 96
 100
 -
#19
 3.4
 20
 1.4
 66
 91
 100
 -
#1
 40
 51
 193
 61
 40
 96
 -
#10
 7.6
 12
 0.5
 80
 26
 94
 -
#33
 0.3
 46
 143
 26
 67
 94
 1
#4
 1.7
 35
 437
 57
 57
 93
 -
#14
 45
 319
 9.7
 59
 25
 93
 9
#32
 33
 62
 51
 0
 45
 92
 47
#11
 2.5
 35
 61
 12
 53
 91
 26
#9
 0.3
 34
 13
 32
 57
 90
 1
#34
 2.6
 70
 1.5
 44
 31
 86
 11
#16
 2.3
 1.8
 92
 0
 59
 81
 22
#17
 7
 4.9
 16
 21
 51
 81
 9
#8
 17
 53
 72
 0
 0
 73
 73
#15
 78
 23
 3.4
 47
 16
 72
 9
#5
 16
 76
 74
 0
 60
 70
 10
#6
 0.2
 19
 57
 0
 66
 66
 0
#20
 2.4
 173
 31
 11
 43
 64
 10
#3
 9
 8.4
 12
 15
 0
 63
 48
#35
 3.7
 9.2
 7.2
 62
 1
 62
 −1
#31
 0.8
 55
 9.6
 41
 38
 52
 −27
#26
 2.4
 17
 9
 43
 0
 43
 0
#25
 12
 42
 3.2
 15
 2
 38
 21
#18
 85
 20
 1.9
 0
 8
 33
 25
#29
 0.9
 62
 31
 0
 64
 27
 −37
#27
 14
 20
 100
 0
 0
 26
 26
#2
 54
 20
 3.1
 6
 5
 18
 7
#36
 53
 6
 6.2
 27
 9
 14
 −22
#7
 23
 11
 15
 0
 5
 0
 −5
#12
 0.3
 29
 7.5
 0
 34
 0
 −34
#21
 6.2
 24
 53
 0
 0
 0
 0
#23
 0.2
 4.2
 20
 0
 2
 0
 −2
#28
 6
 17
 3.2
 0
 0
 0
 0
#30 2.4 90 34 0 0 0 0

34 AML samples used in this study ordered by magnitude of response to tipifarnib + GO (column second from the right).

1% of cells lost after 48 hours treatment (compared to untreated control).

2 Δtox = cell loss with drug combination – (cell loss with tipifarnib + cell loss with GO). No values are displayed when cell loss with tipifarnib + cell loss with GO= > 100%.